Get all premium features to the best stock analysis tool

Hims & Hers Health shares rallied to ~$27 after the early-March Novo deal before resetting to ~$20, still leaving the stock ~40% above prior coverage levels. Short interest remains elevated at ~83.3M shares (~40% float), while days-to-cover expanded from ~1.0 to ~3.6. Short volume intensity declined from ~62–64% during the selloff to ~45%, signaling reduced marginal short pressure.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisk's FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill.1 As a part of a collaboration with Novo Nordisk, Hims & Hers is making it simpler for customers to access FDA-approved GLP-1 medications which are now available at more affordable prices, with more doses and deli.

Hims resolved its legal dispute with Novo Nordisk, removing a major overhang and enabling it to offer branded drugs. Valuations have not recovered to pre-lawsuit levels as persistent insider selling and changes in disclosure have weighed negatively on sentiment. Consensus underestimates the inherent story in Hims emanating from growth in subscribers, sustainability and penetration in new products & markets.

Hims & Hers and Doximity are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.

LOS ANGELES, March 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock?

Investors interested in Medical Info Systems stocks are likely familiar with Inspire Medical Systems (INSP) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks offers value investors a better bang for their buck right now?